Non-Calcium-Containing Phosphate Binders: Comparing Efficacy, Safety, and Other Clinical Effects
Nephron Clinical Practice, 04/30/2012
Frazao JM et al. – Phosphate–binder therapy for hyperphosphataemia is key to the treatment of patients with chronic kidney disease–mineral and bone disorder. Calcium–free phosphate binders are increasingly favoured since calcium–based agents potentially cause harmful calcium overload and vascular calcification that confound the benefits of reducing serum phosphorus. Several calcium–free phosphate binders are available, including the non–absorbed agent sevelamer and the absorbed agents, e.g. lanthanum and magnesium salts.